{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T12:37:26Z","timestamp":1790339846370,"version":"4.1.0"},"reference-count":32,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2018,3,12]],"date-time":"2018-03-12T00:00:00Z","timestamp":1520812800000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003550","name":"Queensland Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003550","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Surgical Oncology"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Patients with in\u2010transit melanoma metastases frequently experience high rates of recurrence, limited overall survival and reduced quality of life. After promising results within a Phase II, multi\u2010center study, PV\u201010 treatment was continued at our institution for patients with in\u2010transit disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methodology<\/jats:title><jats:p>An open\u2010label, non\u2010randomized, prospective study was performed at the Princess Alexandra Hospital, Queensland, Australia. Patients were treated with PV\u201010 in accordance with the treatment protocol established during a previous Phase II study. The primary outcome was the complete response of treated lesions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Forty\u2010five patients were enrolled over a total of 82 treatment episodes from July 2008 to December 2015. With sequential PV\u201010 treatments the complete response rate was 42% and overall response rate 87% on an intention to treat analysis. The median follow\u2010up duration was 22 months and the median overall survival was 25 months from first PV\u201010 treatment. Having fewer than 15 metastases at the time of treatment was associated with a complete response (<jats:italic>P<\/jats:italic>\u2009=\u20090.03).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Intralesional PV\u201010 provided rapid lesion\u2010specific ablation of melanoma metastases with well\u2010tolerated local effects and minimal systemic adverse events. This therapy should be considered for patients with multiple accessible deposits within the spectrum of low to moderate disease volume.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jso.24921","type":"journal-article","created":{"date-parts":[[2018,3,12]],"date-time":"2018-03-12T17:52:43Z","timestamp":1520877163000},"page":"579-587","source":"Crossref","is-referenced-by-count":44,"title":["Intralesional PV\u201010 for the treatment of in\u2010transit melanoma metastases\u2014Results of a prospective, non\u2010randomized, single center study"],"prefix":"10.1002","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1785-3985","authenticated-orcid":false,"given":"Tavis A.","family":"Read","sequence":"first","affiliation":[{"name":"Queensland Melanoma Project Princess Alexandra Hospital Brisbane Australia"},{"name":"Faculty of Medicine The University of Queensland, Southern Clinical School, Princess Alexandra Hospital Brisbane Australia"},{"name":"School of Medicine Griffith University Gold Coast Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Smith","sequence":"additional","affiliation":[{"name":"School of Medicine Griffith University Gold Coast Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Thomas","sequence":"additional","affiliation":[{"name":"Queensland Melanoma Project Princess Alexandra Hospital Brisbane Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"David","sequence":"additional","affiliation":[{"name":"School of Health and Rehabilitation Sciences The University of Queensland Brisbane Australia"},{"name":"School of Medicine and Public Health The University of Newcastle Newcastle Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Foote","sequence":"additional","affiliation":[{"name":"Queensland Melanoma Project Princess Alexandra Hospital Brisbane Australia"},{"name":"Faculty of Medicine The University of Queensland, Southern Clinical School, Princess Alexandra Hospital Brisbane Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wagels","sequence":"additional","affiliation":[{"name":"Queensland Melanoma Project Princess Alexandra Hospital Brisbane Australia"},{"name":"Faculty of Medicine The University of Queensland, Southern Clinical School, Princess Alexandra Hospital Brisbane Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Barbour","sequence":"additional","affiliation":[{"name":"Queensland Melanoma Project Princess Alexandra Hospital Brisbane Australia"},{"name":"Faculty of Medicine The University of Queensland, Southern Clinical School, Princess Alexandra Hospital Brisbane Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Mark","family":"Smithers","sequence":"additional","affiliation":[{"name":"Queensland Melanoma Project Princess Alexandra Hospital Brisbane Australia"},{"name":"Faculty of Medicine The University of Queensland, Southern Clinical School, Princess Alexandra Hospital Brisbane Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,3,12]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.4799"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1245\/ASO.2005.05.025"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-014-4100-0"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.22029"},{"key":"e_1_2_8_6_1","first-page":"1340","article-title":"In transit melanoma: an individualized approach","volume":"25","author":"Grotz TE","year":"2011","journal-title":"Oncology"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers7030830"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104621"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60868-X"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1203421"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.suc.2014.07.004"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.23554"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008390-200609001-00012"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0b013e32831328c7"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0068561"},{"key":"e_1_2_8_17_1","article-title":"The potential of intralesional rose bengal to stimulate T\u2010cell mediated anti\u2010tumor responses","volume":"6","author":"Maker AV","year":"2015","journal-title":"J Clin Cell Immunol"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9247"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.473"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.24580"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-014-4169-5"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.24311"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.1989.01410090061014"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-009-0717-9"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.1993.tb00989.x"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.3377"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.21968"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-015-4969-2"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2009-0325"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-012-2782-8"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.3109\/02656736.2013.802374"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.32.15_suppl.9028"}],"container-title":["Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjso.24921","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jso.24921","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jso.24921","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jso.24921","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T04:11:04Z","timestamp":1694319064000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jso.24921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1002\/jso.24921"],"URL":"https:\/\/doi.org\/10.1002\/jso.24921","archive":["Portico"],"relation":{},"ISSN":["0022-4790","1096-9098"],"issn-type":[{"value":"0022-4790","type":"print"},{"value":"1096-9098","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3]]}}}